Graduate Student Resources
Return back to Faculty Listing
Joshua A. Lile, Ph.D.
(Wake Forest University School of Medicine, 2002)
Dr. Lile’s research interests focus on the pharmacological and behavioral determinants of, and potential treatments for, drug addiction. To this end, Dr. Lile is conducting several human laboratory research projects in three primary area:
1) The primary focus of my current research is to screen potential medications for cannabis-use disorders using an efficient, evidence-based progression of laboratory procedures. This goal is accomplished using a step-wise screening process to first identify targets and/or specific compounds using pharmacologically specific drug-discrimination procedures, followed by an evaluation of the ability of maintenance on a putative pharmacotherapy to attenuate the reinforcing effects of cannabis under controlled laboratory conditions as well as cannabis use in the natural environment. Supported by K02 DA031766 (Lile) and R01 DA025605 (Lile).
2) In collaboration with Drs. Craig Rush and Bill Stoops, Dr. Lile is pursuing medications development for the treatment of stimulant use disorders using drug self-administration models. Pharmacological strategies such as agonist replacement and indirect attenuation of dopamine activity are being tested in stimulant-dependent individuals. Supported by R01 DA025591 (Rush) and DA025032 (Rush).
3) Dr. Lile is involved in a series of studies, in collaboration with Dr. Tom Kelly, to investigate the influence of individual differences such personality and gonadal sex hormone status on the behavioral effects of drugs. This research integrates behavioral measures and functional magnetic resonance imaging (fMRI) in the same subjects to examine the manner and anatomical locations in which these factors influence neurobehavioral outcomes. Supported by P50 DA005312 (Kelly).
Dr. Lile received the prestigious College on Problems of Drug Dependence Joseph Cochin Young Investigator Award. He also received a priority score of 20 (7th percentile) on an R01 application to develop a translational platform for cocaine dependence medications development in monkeys and humans in collaboration with colleagues at Virginia Commonwealth University. This grant has been approved by NIDA council and a response to a Just-In-Time request directly from NIDA has been submitted. Dr. Lile is currently in the 2nd of a 5-year K02 career development award to support his efforts towards medications development for cannabis-use disorders. This research is also funded by an ongoing 4-year R01, and by a pilot project to Dr. Lile from the UK Center for Clinical and Translational Research. These studies have identified promising neurobiological targets to manage cannabis dependence, and are testing potential medications using innovative outpatient maintenance procedures to determine pharmacotherapy effects on cannabis use in the laboratory and in the natural environment. Dr. Lile published two first author manuscripts this year based on this research, and presented results at the College on Problems of Drug Dependence and the International Cannabinoid Research Society conferences. A third first author manuscript is in the final stages of editing and will be submitted by the end of 2012. Another active area of research for Dr. Lile has been the development of pharmacotherapies for the treatment of stimulant dependence in collaboration with Drs. Rush and Stoops. Dr. Lile served as a Co-Investigator on three R01 awards and an R21 to this end, and completed two related studies this year. His involvement in this research resulted in three co-authored publications, a conference presentation, as well as two R01 and two R21 grant submissions as co-PI, in addition to the application as PI noted above. Dr. Lile is also serving as a pro-bono clinical consultant on an R01 conducted at VCU to evaluate putative methamphetamine pharmacotherapies in non-human primates. A third area of involvement for Dr. Lile has been the study of the influence of individual differences such as personality factors on vulnerability to drug use in collaboration with Dr. Kelly, which is supported by a P50 Center on Drug Abuse Translation (CDART) that was renewed for funding this year. His involvement in this research resulted in three conference presentations. Another team science endeavor was Dr. Lile’s assistance with a P50 application, the UK/Lovelace Respiratory Research Institute Center of Excellence in Emerging Tobacco Products Research. As a regular-title series faculty member, Dr. Lile was able to allocate effort towards education by serving as a Co-Instructor for BSC 731, Methods and Technologies in Clinical and Translational Science, and MD 811, Introduction to Clinical Medicine, as well as giving an invited lecture in PSY 780, Problems in Psychology. Worth noting are the excellent course reviews submitted by the students in MD 811. He also served as a dissertation committee member for Mr. Dustin Lee, a Psychology graduate student, and was included as training faculty on the competing renewal application to continue the NIDA T32 training grant in the Behavioral Science Department. Dr. Lile has provided service to the academic and research community by giving two community education lectures and reviewing 13 manuscripts for 8 different journals. Lastly, he has continued his service as a regular member of the University of Kentucky Institutional Review Board.
Representative Publications (Full CV)
Lile JA, Kelly TH and Hays LR (2011). Separate and combined effects of the GABA reuptake inhibitor tiagabine and D9-THC in humans discriminating D9-THC. Drug and Alcohol Dependence, Epub ahead of print. PMID: 21975195.
Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR (2011). Subjective and physiological effects of acute intranasal methamphetamine during extended-release alprazolam maintenance. Drug and Alcohol Dependence, Epub ahead of print. PMID: 21737214.
Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR (2011). Discriminative-stimulus, subject-rated, performance and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. Journal of Psychopharmacology, Epub ahead of print. PMID: 20952456.
Lile JA, Kelly TH and Hays LR (2011). Separate and combined effects of the cannabinoid agonists nabilone and D9-THC in humans discriminating D9-THC. Drug and Alcohol Dependence, 116: 86-92. PMID: 21227600. PMCID: PMC3089804.
Lile JA, Babalonis S, Emurian C, Martin CA, Wermeling D, Kelly TH (2011). Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects. Journal of Clinical Pharmacology. 51: 899-907. PMID: 20671295 PMCID: In Process.
Lile JA, Kelly TH and Hays LR (2010). Substitution profile of the cannabinoid agonist nabilone in humans discriminating D9-tetrahydrocannabinol. Clinical Neuropharmacology 33: 235-42. PMID: 20838217. PMCID: PMC2712322.
Lile JA, Kelly TH and Hays LR (2010) The reinforcing, self-reported, performance and physiological effects of D9-THC, triazolam, hydromorphone and methylphenidate in cannabis users. Behavioural Pharmacology, 21: 29-38. PMID: 19949319. PMCID: PMC2903043.
Lile JA, Kelly TH, Pinsky DJ, and Hays LR (2009) Substitution profile for D9-THC, triazolam, hydromorphone and methylphenidate in humans discriminating D9-THC. Psychopharmacology, 203 (Special Issue on the Stimulus Properties of Drugs): 241-250. PMID: 19018520 PMCID: PMC2712322.
Lile JA, Stoops WW, Hays LR and Rush CR (2008). The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: Increased aripiprazole dose and maintenance period. The American Journal of Drug and Alcohol Abuse, 34: 721-9. PMID: 18855244 PMCID: PMC2713051.
Lile JA, Stoops WW, Wagner FP, Glaser PEA and Rush CR (2005). Oxazepam does not modulate the behavioral effects of d-amphetamine in humans. Pharmacology, Biochemistry and Behavior, 82: 270-9. PMID: 16182353.
Lile JA, Stoops WW, Vansickel AR, Glaser PEA, Hays LR and Rush CR (2005) Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of d-amphetamine in humans. Neuropsychopharmacology, 30: 2103-14. PMID: 15988473.
Lile JA, Stoops WW, Hays LR and Rush CR (2004) Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug and Alcohol Dependence 76: 81-91. PMID: 15380292.
Lile JA, Stoops WW, Allen TS, Glaser PEA, Hays LR and Rush CR (2004) Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology 171: 441-9. PMID: 14504683.
|Comments and Corrections | An Equal Opportunity University | Jobs | Terms, Conditions and Accessibility Statements | Privacy|
© 2012, University of Kentucky College of Medicine, 138 Leader Ave., Lexington, Kentucky, USA 40506-9983
Student Affairs: (859) 323-5261 · Admissions: (859) 323-6161 · Clinical Questions: (859) 257-1000 · Dean's Office: (859) 323-6582
Page last updated Tuesday, February 05, 2013